- This event has passed.
A Model to Value Hearing Disability Caused by Congenital Cytomegalovirus
April 20 @ 9:00 am - 10:00 am EDT
The provisional plan is a one hour time slot composed of 5 minutes of initial housekeeping, an approximate 40 minute presentation and 15 minutes for discussion.
Speaker: Dr. Bernarda Zamora (she/her), Research Fellow in Health Economics, NIHR London IVD Cooperative (MIC), Imperial College London
Background: Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of sensorineural hearing loss (SNHL) and therefore an important target for effective treatment. More than 50% of children suffering cCMV pathology are asymptomatic at birth, with symptoms manifesting months or years later. The lack of diagnosis add to uncertainty in incidence of SNHL caused by cCMV and in burden of disease.
Methods: The health economics model uses a different perspective and methods than previously used by the York Health Economics Consortium in their economic evaluation work commissioned by CMV Action. A willingness-to-pay approach for hearing loss disability is adopted. This approach combines the incidence of congenital HCMV (cCMV) with that of symptomatic and asymptomatic SNHL. Also,
uncertainty from undiagnosed SNHL is partly attributed to cCMV.
Results: Overall, over the 2020 birth cohort, a total of 640 cases of SNHL are caused by cCMV, and the range of uncertainty is between 298 and 986 cases. According to the Global Burden of Disease disability weights for hearing loss (0.0307) and the life expectancy for the 2020 birth cohort (89 years), a person losses and average of 2.72 years of life due to hearing disability. Considering the estimated Value of Life at £995,027 consistent to the £30,000 per QALY threshold adopted by NICE, the average per person value of life lost to hearing disability is £30,506, that for all patient affected amounts £19,513,607. These figures can be compared at patient level with cost-based estimates at £21,235. which is below the average value of life lost due to hearing loss we have estimated.
Conclusions: The value of preventing and avoiding hearing loss caused by cCMV is larger than the direct clinical costs previously estimated which supports adoption by the NHS of a diagnostic tool to screen for the presence of cCMV during the current universal hearing newborn screening programme.